MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis

Autores de IIS La Fe

• 

  Javier De La Rubia Comos

  Autor

Participantes ajenos a IIS La Fe

• Martin T.
• Hajek R.
• Moreau P.
• Augustson B.
• Castro N.
• Pika T.
• Delimpasi S.
• Maiolino A.
• Reiman A.
• Martinez-Lopez J.
• Mikhael J.
• Yong K.
• Risse M.-L.
• Casca F.
• Marion S.
• Macé S.
• Dimopoulos M.A.

Grupos

• Hematología y Hemoterapia

Abstract

Abstract no disponible

Keywords

• carfilzomib; dexamethasone; isatuximab; Article; bone marrow biopsy; cancer combination chemotherapy; cancer recurrence; cancer survival; clinical outcome; controlled study; follow up; high throughput sequencing; human; human tissue; laboratory test; major clinical study; Mantel Haenszel test; minimal residual disease; multicenter study; multiple myeloma; outcome assessment; phase 3 clinical trial; progression free survival; randomized controlled trial; treatment duration; treatment response